Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

3CJO

Crystal structure of KSP in complex with inhibitor 30

3CJO の概要
エントリーDOI10.2210/pdb3cjo/pdb
分子名称Kinesin-like protein KIF11, MAGNESIUM ION, ADENOSINE-5'-DIPHOSPHATE, ... (5 entities in total)
機能のキーワードksp, ksp-inhibitor complex, atp-binding, cell cycle, cell division, coiled coil, microtubule, mitosis, motor protein, nucleotide-binding, phosphoprotein
由来する生物種Homo sapiens (Human)
細胞内の位置Cytoplasm: P52732
タンパク質・核酸の鎖数2
化学式量合計83670.79
構造登録者
Yan, Y. (登録日: 2008-03-13, 公開日: 2008-07-01, 最終更新日: 2023-08-30)
主引用文献Cox, C.D.,Coleman, P.J.,Breslin, M.J.,Whitman, D.B.,Garbaccio, R.M.,Fraley, M.E.,Buser, C.A.,Walsh, E.S.,Hamilton, K.,Schaber, M.D.,Lobell, R.B.,Tao, W.,Davide, J.P.,Diehl, R.E.,Abrams, M.T.,South, V.J.,Huber, H.E.,Torrent, M.,Prueksaritanont, T.,Li, C.,Slaughter, D.E.,Mahan, E.,Fernandez-Metzler, C.,Yan, Y.,Kuo, L.C.,Kohl, N.E.,Hartman, G.D.
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer.
J.Med.Chem., 51:4239-4252, 2008
Cited by
PubMed Abstract: Inhibition of kinesin spindle protein (KSP) is a novel mechanism for treatment of cancer with the potential to overcome limitations associated with currently employed cytotoxic agents. Herein, we describe a C2-hydroxymethyl dihydropyrrole KSP inhibitor ( 11) that circumvents hERG channel binding and poor in vivo potency, issues that limited earlier compounds from our program. However, introduction of the C2-hydroxymethyl group caused 11 to be a substrate for cellular efflux by P-glycoprotein (Pgp). Utilizing knowledge garnered from previous KSP inhibitors, we found that beta-fluorination modulated the p K a of the piperidine nitrogen and reduced Pgp efflux, but the resulting compound ( 14) generated a toxic metabolite in vivo. Incorporation of fluorine in a strategic, metabolically benign position by synthesis of an N-methyl-3-fluoro-4-(aminomethyl)piperidine urea led to compound 30 that has an optimal in vitro and metabolic profile. Compound 30 (MK-0731) was recently studied in a phase I clinical trial in patients with taxane-refractory solid tumors.
PubMed: 18578472
DOI: 10.1021/jm800386y
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.28 Å)
構造検証レポート
Validation report summary of 3cjo
検証レポート(詳細版)ダウンロードをダウンロード

246905

件を2025-12-31に公開中

PDB statisticsPDBj update infoContact PDBjnumon